Xarelto

2.5 mg: In combination w/ ASA alone or w/ ASA plus clopidogrel or ticlopidine for prevention of CV death in adult patients after acute coronary syndrome (ACS) w/ elevated biomarkers. In combination w/ aspirin to reduce risk of major CV events (CV death, MI & stroke) in adult patients w/ chronic CAD or peripheral artery disease (PAD) at high risk of ischemic events. 10 mg: Prevention of VTE in patients undergoing total hip or knee replacement surgery. 15 mg & 20 mg: Prevention of stroke & systemic embolism in patients w/ nonvalvular atrial fibrillation. 10 mg, 15 mg & 20 mg: Treatment of DVT & PE; prevention of recurrent DVT & PE in adult.

2.5 mg ACS 2.5 mg bd taken w/ daily dose of ASA 75-100 mg &/or clopidogrel 75 mg or standard daily dose of ticlopidine. CAD or PAD 2.5 mg bd in combination w/ daily dose of ASA 75-100 mg. 10 mg Prevention of VTE in patients undergoing total hip or knee replacement surgery 10 mg once daily. Initial dose should be taken 6-10 hr after surgery, provided that haemostasis has been established. Duration of treatment: Major hip surgery: 5 wk. Major knee surgery: 2 wk. Prevention of recurrent DVT & PE 10 mg or 20 mg once daily following completion of at least 6 mth therapy. Max dose: 10 mg or 20 mg. 15 mg & 20 mg Prevention of stroke & systemic embolism in patients w/ nonvalvular atrial fibrillation 20 mg once daily. 10 mg, 15 mg & 20 mg Treatment of DVT & PE; prevention of recurrent DVT & PE Adult Initially 15 mg bd for day 1-21 (max: 30 mg), followed by 20 mg once daily on day 22 & onwards (max: 20 mg).

2.5 & 10 mg FC tab: May be taken with or without food: May crush or mix w/ water or soft foods (eg, applesauce) for patients who are unable to swallow whole tab. Crushed tab may be given through gastric tubes by mixing in small amount of water. 15 & 20 mg FC tab: Should be taken with food.

Hypersensitivity. Clinically significant active bleeding. Hepatic disease associated w/ coagulopathy & clinically relevant bleeding risk including cirrhotic patients w/ Child-Pugh B & C. Lesion or condition if considered to be a significant risk of major bleeding including current or recent GI ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophth surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities. Concomitant treatment w/ any other anticoagulants (eg, unfractionated heparin), LMWH (eg, enoxaparin, dalteparin) & heparin derivatives (eg, fondaparinux). Pregnancy & lactation. 2.5 mg: Concomitant treatment of ACS w/ antiplatelet therapy in patients w/ prior stroke or transient ischaemic attack. 2.5 mg & 10 mg: Concomitant use w/ oral anticoagulants (eg, warfarin, apixaban, dabigatran).

Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)

B01AF01 - rivaroxaban ; Belongs to the class of direct factor Xa inhibitors. Used in the treatment of thrombosis.

POM